Comparative Pharmacology
Head-to-head clinical analysis: ASHLYNA versus KYLEENA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASHLYNA versus KYLEENA.
ASHLYNA vs KYLEENA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ASHLYNA is a combination of ethinyl estradiol and drospirenone. The contraceptive effect is based on inhibition of ovulation and alterations in cervical mucus and endometrial receptivity. Drospirenone has antimineralocorticoid and antiandrogenic activity.
Levonorgestrel is a progestin that suppresses endometrial proliferation, thickens cervical mucus, and induces endometrial atrophy. It also partially inhibits ovulation.
One tablet (0.02 mg ethinyl estradiol / 3 mg drospirenone) orally once daily for 21 days, followed by 7 placebo tablets.
KYLEENA (levonorgestrel-releasing intrauterine system 19.5 mg) is inserted into the uterine cavity by a healthcare professional. One system releases levonorgestrel at approximately 17.5 mcg/day initially, decreasing to 7.4 mcg/day after 1 year and 5.1 mcg/day after 3 years, and is effective for up to 5 years.
None Documented
None Documented
Terminal half-life: 12–15 hours; clinical context: supports once-daily dosing
Terminal elimination half-life is approximately 25 hours (range 18–30 hours) after repeated dosing; supports once-daily dosing but not applicable for IUD as systemic absorption is minimal.
Renal: ~60% unchanged; fecal: ~30% (metabolites); biliary: ~10%
Renal (fecal negligible). Levonorgestrel is extensively metabolized; metabolites are excreted primarily in urine (40–68%) and to a lesser extent in feces (16–48%).
Category C
Category C
Contraceptive
Contraceptive